Market Closed -
Other stock markets
|
Pre-market 03:34:31 am | |||
0.396 EUR | -1.00% | 0.396 | 0.00% |
Sales 2023 | 3M 3.24M | Sales 2024 * | 4.4M 4.75M | Capitalization | 30.93M 33.42M |
---|---|---|---|---|---|
Net income 2023 | -26M -28.1M | Net income 2024 * | -26M -28.1M | EV / Sales 2023 | 8.55 x |
Net Debt 2023 * | 29.4M 31.77M | Net Debt 2024 * | 57.8M 62.46M | EV / Sales 2024 * | 20.2 x |
P/E ratio 2023 |
-0.85
x | P/E ratio 2024 * |
-0.69
x | Employees | 23 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 90.77% |
Latest transcript on GenSight Biologics S.A.
1 day | -1.00% | ||
1 week | -12.49% | ||
1 month | -0.75% | ||
3 months | -13.44% | ||
6 months | -43.02% | ||
Current year | -13.91% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | - | 21-05-18 | |
Thomas Gidoin
DFI | Director of Finance/CFO | 41 | 15-05-31 |
Scott Jeffers
CTO | Chief Tech/Sci/R&D Officer | - | 22-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Michael Wyzga
CHM | Chairman | 69 | 13-09-30 |
Peter Goodfellow
BRD | Director/Board Member | 72 | 14-05-31 |
José-Alain Sahel
FOU | Founder | 68 | 11-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-03-27 | 0.396 | -1.00% | 78,279 |
24-03-26 | 0.4 | -0.25% | 57,643 |
24-03-25 | 0.401 | -10.29% | 301,125 |
24-03-22 | 0.447 | +1.94% | 36,323 |
24-03-21 | 0.4385 | -3.09% | 123,647 |
Real-time Euronext Paris, March 27, 2024 at 12:35 pm EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-13.91% | 33.47M | |
+2.56% | 108B | |
+10.02% | 104B | |
+7.19% | 23.66B | |
-11.91% | 22.1B | |
-3.29% | 19.71B | |
-35.98% | 18.2B | |
-14.02% | 16.19B | |
+4.61% | 13.72B | |
+35.05% | 12.22B |